Radiopharmaceuticals Market By End User (Hospitals and Clinics, Medical Imaging Centers, Others), By Radioisotope (Technetium 99m, Gallium 68, Iodine I, Fluorine 18, Copper 64, Strontium 89, Yttrium 90, Radium 223, Actinium 225, Lutetium 177, Copper 67, T

Radiopharmaceuticals Market By End User (Hospitals and Clinics, Medical Imaging Centers, Others), By Radioisotope (Technetium 99m, Gallium 68, Iodine I, Fluorine 18, Copper 64, Strontium 89, Yttrium 90, Radium 223, Actinium 225, Lutetium 177, Copper 67, Terbium 161, Zirconium 89, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic): Global Opportunity Analysis and Industry Forecast, 2024-2033


The radiopharmaceuticals market was valued at $7.9 billion in 2023 and is estimated to reach $21.8 billion by 2033, exhibiting a CAGR of 10.6% from 2024 to 2033. Radiopharmaceuticals are medications that include radioactive versions of chemical elements known as radioisotopes. Depending on the type of radiation they emit, radioisotopes can be used to diagnose or treat a variety of medical diseases. Their uses range from examining and treating various organs, including the brain, heart, kidney, and bone, to the treatment of cancer and hyperthyroidism. Radiopharmaceuticals are administered to patients via injection or orally, and they may be monitored and analyzed using external medical equipment and testing. Most nations have specialized safety measures in place to safeguard patients and health workers from the potential harmful effects of these pharmaceuticals.
The radiopharmaceuticals market is primarily driven by the increase in prevalence of chronic diseases, rise in technological advancements, and growth in applications in diagnostic and therapeutic procedures. As the prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions continues to rise, there is a growing demand for effective diagnostic tools and targeted treatments. Radiopharmaceuticals, with their ability to provide precise imaging and therapeutic options, are increasingly recognized as valuable tools in the fight against these diseases. In addition, advancements in imaging techniques such as PET and SPECT have significantly improved the accuracy and efficiency of diagnosis, enabling early detection and better management of diseases propels the market growth. Additionally, the emergence of personalized medicine approaches has fueled the demand for radiopharmaceuticals, as they allow for tailored treatments on the basis of individual patient characteristics and molecular targets. However, the high cost associated with the development and production of radiopharmaceuticals can be prohibitive, thus hindering the market growth. This includes expenses related to research, clinical trials, and manufacturing processes, and regulatory compliance. The complex nature of radiopharmaceuticals also requires specialized infrastructure and expertise, further adding to the financial burden. In contrast, ongoing R&D activities for radiopharmaceuticals are increasingly being explored for use in areas such as theranostics, which involves combining diagnostic imaging with targeted therapy that provides lucrative opportunities for the market growth. The radiopharmaceuticals market is segmented on the basis of type, application, radioisotope, end user, and region. On the basis of type, the market is bifurcated into diagnostic, and therapeutic. On the basis of application, the market is classified into cancer, cardiology and others. The cancer segment is further classified into prostate cancer, breast cancer, gastrointestinal cancer, lung cancer, brain tumors, and others. The others segment further bifurcated into Neurological Applications and other applications. On the basis of radioisotope, the market is classified into Iodine I, Gallium 68, Technetium 99m, Fluorine 18, Copper 64, Strontium 89, Yttrium 90, Radium 223, Actinium 225, Lutetium 177, Copper 67, Terbium 161, Zirconium 89, and others. On the basis of end user, the market is categorized into hospitals and clinics, medical imaging centers, and others. On the basis of region, the market is studied across North America (U.S. and Canada), Europe (Germany, UK, France, Spain, Italy, and Rest of Europe), Asia-Pacific (India, China, Australia, Japan, South Korea, Thailand, Malaysia, Indonesia, Singapore, Taiwan, Province Of China, and Rest of Asia-Pacific), and LAMEA (Brazil and Rest of LAMEA). Major key players that operate in the global radiopharmaceuticals market are Bayer AG, Cardinal Health, Eli Lilly and Company, Bracco, Isotopia Molecular Imaging Ltd., Actinium Pharmaceuticals, Inc., Novartis AG, Curium Pharma, Nihon Medi-Physics Co. Ltd., Jubilant Pharmova Limited, Eckert & Ziegler, NorthStar Radioisotopes, The State Atomic Energy Corporation ROSATOM, SOFIE, Lantheus, Telix Pharmaceuticals Limited, Clarity Pharmaceuticals, Fusion Pharmaceuticals Inc., PRECIRIX, ITM Isotope Technologies Munich SE, GE Healthcare, South African Nuclear Energy Corporation (Necsa), and Eczacibasi. Key players operating in the market have adopted agreement, acquisition, expansion, clinical trial, product approval, product upgrade, contract, product development, collaboration, geographical expansion, joint venture, and expansion, as their key strategies to expand their product portfolio.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the radiopharmaceuticals market analysis from 2023 to 2033 to identify the prevailing radiopharmaceuticals market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global radiopharmaceuticals market trends, key players, market segments, application areas, and market growth strategies.
Patient/epidemiology data at country, region, global level
Regulatory Guidelines
Historic market data

Key Market Segments

By End User

Hospitals and Clinics
Medical Imaging Centers
Others

By Radioisotope

Technetium 99m
Gallium 68
Iodine I
Fluorine 18
Copper 64
Strontium 89
Yttrium 90
Radium 223
Actinium 225
Lutetium 177
Copper 67
Terbium 161
Zirconium 89
Others

By Application

Cancer
Type
Prostate Cancer
Breast Cancer
Gastrointestinal Cancer
Lung Cancer
Brain Tumors
Others
Cardiology
Others
Type
Neurological Applications
Other Applications

By Type

Diagnostic
Therapeutic

By Region

North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Thailand
Malaysia
Indonesia
Singapore
Taiwan, Province Of China
Rest of Asia-Pacific
LAMEA
Brazil
Rest of LAMEA
Key Market Players
Cardinal Health
Eli Lilly and Company
Novartis AG
Jubilant Pharmova Limited
The State Atomic Energy Corporation ROSATOM
SOFIE
Telix Pharmaceuticals Limited
Clarity Pharmaceuticals
PRECIRIX
NorthStar Medical Radioisotopes
South African Nuclear Energy Corporation (Necsa)
Bayer AG
Bracco
Curium Pharma
Eckert & Ziegler
Lantheus
Nihon Medi-Physics Co. Ltd
Isotopia Molecular Imaging
ITM Isotope Technologies Munich SE
GE Healthcare
Actinium Pharmaceuticals, Inc.
Fusion Pharmaceuticals Inc.
Eczacibasi


CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate low threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. High intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of chronic diseases
3.4.1.2. Rise in adoption of strategies by key players
3.4.1.3. Rise in R&D activities
3.4.2. Restraints
3.4.2.1. High cost of development and implementation of radiopharmaceuticals
3.4.3. Opportunities
3.4.3.1. Rise in number of pipeline products
CHAPTER 4: RADIOPHARMACEUTICALS MARKET, BY END USER
4.1. Overview
4.1.1. Market size and forecast
4.2. Hospitals and Clinics
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Medical Imaging Centers
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Technetium 99m
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Gallium 68
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Iodine I
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Fluorine 18
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Copper 64
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
5.7. Strontium 89
5.7.1. Key market trends, growth factors and opportunities
5.7.2. Market size and forecast, by region
5.7.3. Market share analysis by country
5.8. Yttrium 90
5.8.1. Key market trends, growth factors and opportunities
5.8.2. Market size and forecast, by region
5.8.3. Market share analysis by country
5.9. Radium 223
5.9.1. Key market trends, growth factors and opportunities
5.9.2. Market size and forecast, by region
5.9.3. Market share analysis by country
5.10. Actinium 225
5.10.1. Key market trends, growth factors and opportunities
5.10.2. Market size and forecast, by region
5.10.3. Market share analysis by country
5.11. Lutetium 177
5.11.1. Key market trends, growth factors and opportunities
5.11.2. Market size and forecast, by region
5.11.3. Market share analysis by country
5.12. Copper 67
5.12.1. Key market trends, growth factors and opportunities
5.12.2. Market size and forecast, by region
5.12.3. Market share analysis by country
5.13. Terbium 161
5.13.1. Key market trends, growth factors and opportunities
5.13.2. Market size and forecast, by region
5.13.3. Market share analysis by country
5.14. Zirconium 89
5.14.1. Key market trends, growth factors and opportunities
5.14.2. Market size and forecast, by region
5.14.3. Market share analysis by country
5.15. Others
5.15.1. Key market trends, growth factors and opportunities
5.15.2. Market size and forecast, by region
5.15.3. Market share analysis by country
CHAPTER 6: RADIOPHARMACEUTICALS MARKET, BY APPLICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Cancer
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.2.4. Cancer Radiopharmaceuticals Market by Type
6.3. Cardiology
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Others
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.4.4. Others Radiopharmaceuticals Market by Type
CHAPTER 7: RADIOPHARMACEUTICALS MARKET, BY TYPE
7.1. Overview
7.1.1. Market size and forecast
7.2. Diagnostic
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Therapeutic
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
CHAPTER 8: RADIOPHARMACEUTICALS MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by End User
8.2.3. Market size and forecast, by Radioisotope
8.2.4. Market size and forecast, by Application
8.2.5. Market size and forecast, by Type
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by End User
8.2.6.1.2. Market size and forecast, by Radioisotope
8.2.6.1.3. Market size and forecast, by Application
8.2.6.1.4. Market size and forecast, by Type
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by End User
8.2.6.2.2. Market size and forecast, by Radioisotope
8.2.6.2.3. Market size and forecast, by Application
8.2.6.2.4. Market size and forecast, by Type
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by End User
8.3.3. Market size and forecast, by Radioisotope
8.3.4. Market size and forecast, by Application
8.3.5. Market size and forecast, by Type
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by End User
8.3.6.1.2. Market size and forecast, by Radioisotope
8.3.6.1.3. Market size and forecast, by Application
8.3.6.1.4. Market size and forecast, by Type
8.3.6.2. France
8.3.6.2.1. Market size and forecast, by End User
8.3.6.2.2. Market size and forecast, by Radioisotope
8.3.6.2.3. Market size and forecast, by Application
8.3.6.2.4. Market size and forecast, by Type
8.3.6.3. UK
8.3.6.3.1. Market size and forecast, by End User
8.3.6.3.2. Market size and forecast, by Radioisotope
8.3.6.3.3. Market size and forecast, by Application
8.3.6.3.4. Market size and forecast, by Type
8.3.6.4. Italy
8.3.6.4.1. Market size and forecast, by End User
8.3.6.4.2. Market size and forecast, by Radioisotope
8.3.6.4.3. Market size and forecast, by Application
8.3.6.4.4. Market size and forecast, by Type
8.3.6.5. Spain
8.3.6.5.1. Market size and forecast, by End User
8.3.6.5.2. Market size and forecast, by Radioisotope
8.3.6.5.3. Market size and forecast, by Application
8.3.6.5.4. Market size and forecast, by Type
8.3.6.6. Rest of Europe
8.3.6.6.1. Market size and forecast, by End User
8.3.6.6.2. Market size and forecast, by Radioisotope
8.3.6.6.3. Market size and forecast, by Application
8.3.6.6.4. Market size and forecast, by Type
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by End User
8.4.3. Market size and forecast, by Radioisotope
8.4.4. Market size and forecast, by Application
8.4.5. Market size and forecast, by Type
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Market size and forecast, by End User
8.4.6.1.2. Market size and forecast, by Radioisotope
8.4.6.1.3. Market size and forecast, by Application
8.4.6.1.4. Market size and forecast, by Type
8.4.6.2. China
8.4.6.2.1. Market size and forecast, by End User
8.4.6.2.2. Market size and forecast, by Radioisotope
8.4.6.2.3. Market size and forecast, by Application
8.4.6.2.4. Market size and forecast, by Type
8.4.6.3. India
8.4.6.3.1. Market size and forecast, by End User
8.4.6.3.2. Market size and forecast, by Radioisotope
8.4.6.3.3. Market size and forecast, by Application
8.4.6.3.4. Market size and forecast, by Type
8.4.6.4. Australia
8.4.6.4.1. Market size and forecast, by End User
8.4.6.4.2. Market size and forecast, by Radioisotope
8.4.6.4.3. Market size and forecast, by Application
8.4.6.4.4. Market size and forecast, by Type
8.4.6.5. South Korea
8.4.6.5.1. Market size and forecast, by End User
8.4.6.5.2. Market size and forecast, by Radioisotope
8.4.6.5.3. Market size and forecast, by Application
8.4.6.5.4. Market size and forecast, by Type
8.4.6.6. Thailand
8.4.6.6.1. Market size and forecast, by End User
8.4.6.6.2. Market size and forecast, by Radioisotope
8.4.6.6.3. Market size and forecast, by Application
8.4.6.6.4. Market size and forecast, by Type
8.4.6.7. Malaysia
8.4.6.7.1. Market size and forecast, by End User
8.4.6.7.2. Market size and forecast, by Radioisotope
8.4.6.7.3. Market size and forecast, by Application
8.4.6.7.4. Market size and forecast, by Type
8.4.6.8. Indonesia
8.4.6.8.1. Market size and forecast, by End User
8.4.6.8.2. Market size and forecast, by Radioisotope
8.4.6.8.3. Market size and forecast, by Application
8.4.6.8.4. Market size and forecast, by Type
8.4.6.9. Singapore
8.4.6.9.1. Market size and forecast, by End User
8.4.6.9.2. Market size and forecast, by Radioisotope
8.4.6.9.3. Market size and forecast, by Application
8.4.6.9.4. Market size and forecast, by Type
8.4.6.10. Taiwan, Province Of China
8.4.6.10.1. Market size and forecast, by End User
8.4.6.10.2. Market size and forecast, by Radioisotope
8.4.6.10.3. Market size and forecast, by Application
8.4.6.10.4. Market size and forecast, by Type
8.4.6.11. Rest of Asia-Pacific
8.4.6.11.1. Market size and forecast, by End User
8.4.6.11.2. Market size and forecast, by Radioisotope
8.4.6.11.3. Market size and forecast, by Application
8.4.6.11.4. Market size and forecast, by Type
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by End User
8.5.3. Market size and forecast, by Radioisotope
8.5.4. Market size and forecast, by Application
8.5.5. Market size and forecast, by Type
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Market size and forecast, by End User
8.5.6.1.2. Market size and forecast, by Radioisotope
8.5.6.1.3. Market size and forecast, by Application
8.5.6.1.4. Market size and forecast, by Type
8.5.6.2. Rest of LAMEA
8.5.6.2.1. Market size and forecast, by End User
8.5.6.2.2. Market size and forecast, by Radioisotope
8.5.6.2.3. Market size and forecast, by Application
8.5.6.2.4. Market size and forecast, by Type
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product mapping of top 10 player
9.4. Competitive dashboard
9.5. Competitive heatmap
9.6. Top player positioning, 2023
CHAPTER 10: COMPANY PROFILES
10.1. Bayer AG
10.1.1. Company overview
10.1.2. Key executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.1.7. Key strategic moves and developments
10.2. Cardinal Health
10.2.1. Company overview
10.2.2. Key executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. Curium Pharma
10.3.1. Company overview
10.3.2. Key executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Key strategic moves and developments
10.4. Eli Lilly and Company
10.4.1. Company overview
10.4.2. Key executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.4.7. Key strategic moves and developments
10.5. Jubilant Pharmova Limited
10.5.1. Company overview
10.5.2. Key executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.5.7. Key strategic moves and developments
10.6. Lantheus
10.6.1. Company overview
10.6.2. Key executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.6.7. Key strategic moves and developments
10.7. ITM Isotope Technologies Munich SE
10.7.1. Company overview
10.7.2. Key executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Key strategic moves and developments
10.8. Telix Pharmaceuticals Limited
10.8.1. Company overview
10.8.2. Key executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.8.7. Key strategic moves and developments
10.9. Eckert & Ziegler
10.9.1. Company overview
10.9.2. Key executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.9.7. Key strategic moves and developments
10.10. Bracco
10.10.1. Company overview
10.10.2. Key executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Key strategic moves and developments
10.11. South African Nuclear Energy Corporation (NECSA)
10.11.1. Company overview
10.11.2. Key executives
10.11.3. Company snapshot
10.11.4. Operating business segments
10.11.5. Product portfolio
10.11.6. Business performance
10.11.7. Key strategic moves and developments
10.12. NorthStar Medical Radioisotopes
10.12.1. Company overview
10.12.2. Key executives
10.12.3. Company snapshot
10.12.4. Operating business segments
10.12.5. Product portfolio
10.12.6. Key strategic moves and developments
10.13. The State Atomic Energy Corporation ROSATOM
10.13.1. Company overview
10.13.2. Key executives
10.13.3. Company snapshot
10.13.4. Operating business segments
10.13.5. Product portfolio
10.13.6. Key strategic moves and developments
10.14. SOFIE
10.14.1. Company overview
10.14.2. Key executives
10.14.3. Company snapshot
10.14.4. Operating business segments
10.14.5. Product portfolio
10.14.6. Key strategic moves and developments
10.15. Isotopia Molecular Imaging
10.15.1. Company overview
10.15.2. Key executives
10.15.3. Company snapshot
10.15.4. Operating business segments
10.15.5. Product portfolio
10.15.6. Key strategic moves and developments
10.16. Fusion Pharmaceuticals Inc.
10.16.1. Company overview
10.16.2. Key executives
10.16.3. Company snapshot
10.16.4. Operating business segments
10.16.5. Product portfolio
10.16.6. Key strategic moves and developments
10.17. Clarity Pharmaceuticals
10.17.1. Company overview
10.17.2. Key executives
10.17.3. Company snapshot
10.17.4. Operating business segments
10.17.5. Product portfolio
10.17.6. Key strategic moves and developments
10.18. Actinium Pharmaceuticals, Inc.
10.18.1. Company overview
10.18.2. Key executives
10.18.3. Company snapshot
10.18.4. Operating business segments
10.18.5. Product portfolio
10.18.6. Business performance
10.18.7. Key strategic moves and developments
10.19. PRECIRIX
10.19.1. Company overview
10.19.2. Key executives
10.19.3. Company snapshot
10.19.4. Operating business segments
10.19.5. Product portfolio
10.19.6. Key strategic moves and developments
10.20. Novartis AG
10.20.1. Company overview
10.20.2. Key executives
10.20.3. Company snapshot
10.20.4. Operating business segments
10.20.5. Product portfolio
10.20.6. Business performance
10.20.7. Key strategic moves and developments
10.21. Nihon Medi-Physics Co. Ltd
10.21.1. Company overview
10.21.2. Key executives
10.21.3. Company snapshot
10.21.4. Operating business segments
10.21.5. Product portfolio
10.22. GE Healthcare
10.22.1. Company overview
10.22.2. Key executives
10.22.3. Company snapshot
10.22.4. Operating business segments
10.22.5. Product portfolio
10.22.6. Business performance
10.22.7. Key strategic moves and developments
10.23. Eczacibasi
10.23.1. Company overview
10.23.2. Key executives
10.23.3. Company snapshot
10.23.4. Operating business segments
10.23.5. Product portfolio
10.23.6. Business performance
10.23.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 02. RADIOPHARMACEUTICALS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2023-2033 ($MILLION)
TABLE 03. RADIOPHARMACEUTICALS MARKET FOR MEDICAL IMAGING CENTERS, BY REGION, 2023-2033 ($MILLION)
TABLE 04. RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2023-2033 ($MILLION)
TABLE 05. GLOBAL RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 06. RADIOPHARMACEUTICALS MARKET FOR TECHNETIUM 99M, BY REGION, 2023-2033 ($MILLION)
TABLE 07. RADIOPHARMACEUTICALS MARKET FOR GALLIUM 68, BY REGION, 2023-2033 ($MILLION)
TABLE 08. RADIOPHARMACEUTICALS MARKET FOR IODINE I, BY REGION, 2023-2033 ($MILLION)
TABLE 09. RADIOPHARMACEUTICALS MARKET FOR FLUORINE 18, BY REGION, 2023-2033 ($MILLION)
TABLE 10. RADIOPHARMACEUTICALS MARKET FOR COPPER 64, BY REGION, 2023-2033 ($MILLION)
TABLE 11. RADIOPHARMACEUTICALS MARKET FOR STRONTIUM 89, BY REGION, 2023-2033 ($MILLION)
TABLE 12. RADIOPHARMACEUTICALS MARKET FOR YTTRIUM 90, BY REGION, 2023-2033 ($MILLION)
TABLE 13. RADIOPHARMACEUTICALS MARKET FOR RADIUM 223, BY REGION, 2023-2033 ($MILLION)
TABLE 14. RADIOPHARMACEUTICALS MARKET FOR ACTINIUM 225, BY REGION, 2023-2033 ($MILLION)
TABLE 15. RADIOPHARMACEUTICALS MARKET FOR LUTETIUM 177, BY REGION, 2023-2033 ($MILLION)
TABLE 16. RADIOPHARMACEUTICALS MARKET FOR COPPER 67, BY REGION, 2023-2033 ($MILLION)
TABLE 17. RADIOPHARMACEUTICALS MARKET FOR TERBIUM 161, BY REGION, 2023-2033 ($MILLION)
TABLE 18. RADIOPHARMACEUTICALS MARKET FOR ZIRCONIUM 89, BY REGION, 2023-2033 ($MILLION)
TABLE 19. RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2023-2033 ($MILLION)
TABLE 20. GLOBAL RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 21. RADIOPHARMACEUTICALS MARKET FOR CANCER, BY REGION, 2023-2033 ($MILLION)
TABLE 22. GLOBAL CANCER RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 23. RADIOPHARMACEUTICALS MARKET FOR CARDIOLOGY, BY REGION, 2023-2033 ($MILLION)
TABLE 24. RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2023-2033 ($MILLION)
TABLE 25. GLOBAL OTHERS RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 26. GLOBAL RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 27. RADIOPHARMACEUTICALS MARKET FOR DIAGNOSTIC, BY REGION, 2023-2033 ($MILLION)
TABLE 28. RADIOPHARMACEUTICALS MARKET FOR THERAPEUTIC, BY REGION, 2023-2033 ($MILLION)
TABLE 29. RADIOPHARMACEUTICALS MARKET, BY REGION, 2023-2033 ($MILLION)
TABLE 30. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 31. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 32. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 33. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 34. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
TABLE 35. U.S. RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 36. U.S. RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 37. U.S. RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 38. U.S. RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 39. CANADA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 40. CANADA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 41. CANADA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 42. CANADA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 43. EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 44. EUROPE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 45. EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 46. EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 47. EUROPE RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
TABLE 48. GERMANY RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 49. GERMANY RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 50. GERMANY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 51. GERMANY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 52. FRANCE RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 53. FRANCE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 54. FRANCE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 55. FRANCE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 56. UK RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 57. UK RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 58. UK RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 59. UK RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 60. ITALY RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 61. ITALY RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 62. ITALY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 63. ITALY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 64. SPAIN RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 65. SPAIN RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 66. SPAIN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 67. SPAIN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 68. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 69. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 70. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 71. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 72. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 73. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 74. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 75. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 76. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
TABLE 77. JAPAN RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 78. JAPAN RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 79. JAPAN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 80. JAPAN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 81. CHINA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 82. CHINA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 83. CHINA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 84. CHINA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 85. INDIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 86. INDIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 87. INDIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 88. INDIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 89. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 90. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 91. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 92. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 93. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 94. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 95. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 96. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 97. THAILAND RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 98. THAILAND RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 99. THAILAND RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 100. THAILAND RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 101. MALAYSIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 102. MALAYSIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 103. MALAYSIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 104. MALAYSIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 105. INDONESIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 106. INDONESIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 107. INDONESIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 108. INDONESIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 109. SINGAPORE RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 110. SINGAPORE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 111. SINGAPORE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 112. SINGAPORE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 113. TAIWAN, PROVINCE OF CHINA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 114. TAIWAN, PROVINCE OF CHINA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 115. TAIWAN, PROVINCE OF CHINA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 116. TAIWAN, PROVINCE OF CHINA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 117. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 118. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 119. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 120. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 121. LAMEA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 122. LAMEA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 123. LAMEA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 124. LAMEA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 125. LAMEA RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
TABLE 126. BRAZIL RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 127. BRAZIL RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 128. BRAZIL RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 129. BRAZIL RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 130. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
TABLE 131. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
TABLE 132. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 133. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 134. BAYER AG: KEY EXECUTIVES
TABLE 135. BAYER AG: COMPANY SNAPSHOT
TABLE 136. BAYER AG: PRODUCT SEGMENTS
TABLE 137. BAYER AG: PRODUCT PORTFOLIO
TABLE 138. BAYER AG: KEY STRATEGIES
TABLE 139. CARDINAL HEALTH: KEY EXECUTIVES
TABLE 140. CARDINAL HEALTH: COMPANY SNAPSHOT
TABLE 141. CARDINAL HEALTH: PRODUCT SEGMENTS
TABLE 142. CARDINAL HEALTH: PRODUCT PORTFOLIO
TABLE 143. CARDINAL HEALTH: KEY STRATEGIES
TABLE 144. CURIUM PHARMA: KEY EXECUTIVES
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings